Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting, Circulation, vol.99, pp.1-7, 1999. ,
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials, JAMA, vol.278, pp.313-321, 1997. ,
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor, Cell, vol.89, pp.331-340, 1997. ,
Beyond LDL cholesterol reduction, Circulation, vol.94, pp.2351-2354, 1996. ,
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men, Am. J. Cardiol, vol.81, pp.36-42, 1998. ,
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease, Atherosclerosis, vol.144, pp.177-184, 1999. ,
Atheroprotective mechanisms of HDL. Atherosclerosis, vol.144, pp.285-301, 1999. ,
Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease, Lancet, vol.1, pp.16-19, 1975. ,
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am. J. Med, vol.62, pp.707-714, 1977. ,
Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease, Curr. Opin. Lipidol, vol.7, pp.209-216, 1996. ,
Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses, Proc. Natl. Acad. Sci. USA, vol.88, pp.434-438, 1991. ,
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits, Circulation, vol.94, pp.713-717, 1996. ,
URL : https://hal.archives-ouvertes.fr/hal-02695034
Pleiotropic effects of statins in atherosclerosis and diabetes, Diabetes Care, vol.23, pp.72-78, 2000. ,
Low-density lipoprotein-independent effects of statins, Curr. Opin. Lipidol, vol.10, pp.543-559, 1999. ,
Direct vascular effects of HMG-CoA reductase inhibitors, Atherosclerosis, vol.137, pp.101-109, 1998. ,
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler. Thromb. Vasc. Biol, vol.18, pp.1671-1678, 1998. ,
Cerivastatin suppresses lipopolysaccharideinduced ICAM-1 expression through inhibition of Rho GTPase in BAEC, Biochem. Biophys. Res. Commun, vol.269, pp.97-102, 2000. ,
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins, Circ. Res, vol.83, pp.683-690, 1998. ,
Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis, Arterioscler. Thromb. Vasc. Biol, vol.17, pp.265-272, 1997. ,
, Current perspectives on statins. Circulation, vol.101, pp.207-213, 2000.
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells, Arterioscler. Thromb. Vasc. Biol, vol.20, pp.556-562, 2000. ,
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature, vol.347, pp.645-650, 1990. ,
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta, Proc. Natl. Acad. Sci. USA, vol.94, pp.4312-4317, 1997. ,
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma, Proc. Natl. Acad. Sci. USA, vol.94, pp.4318-4323, 1997. ,
Peroxisome proliferatoractivated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging, Curr. Opin. Lipidol, vol.10, pp.151-159, 1999. ,
Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, vol.98, pp.2088-2093, 1998. ,
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators, Nature, vol.393, pp.790-793, 1998. ,
Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway, Circ. Res, vol.85, pp.394-402, 1999. ,
Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissueselective manner in the rat, Arterioscler. Thromb, vol.12, pp.286-294, 1992. ,
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice, J. Clin. Invest, vol.97, pp.2408-2416, 1996. ,
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element, J. Biol. Chem, vol.269, pp.31012-31018, 1994. ,
A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity, Mol. Endocrinol, vol.13, pp.1535-1549, 1999. ,
Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation, J. Lipid Res, vol.40, pp.2099-2110, 1999. ,
RhoG GTPase controls a pathway that independently activates Rac1 and Cdc42Hs, Mol. Biol. Cell, vol.9, pp.1379-1394, 1998. ,
Activation of proliferator-activated receptors ? and ? induces apoptosis of human monocyte-derived macrophages, J. Biol. Chem, vol.273, pp.25573-25580, 1998. ,
Lovastatin increases apolipoprotein A-I levels in subjects with isolated reductions in high density lipoproteins, Circulation, vol.84, 1991. ,
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism, Genes Dev, vol.10, pp.1096-1107, 1996. ,
Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a, J. Clin. Invest, vol.98, pp.1575-1584, 1996. ,
Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes, J. Biol. Chem, vol.274, pp.35832-35839, 1999. ,
ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand, Proc. Natl. Acad. Sci. USA, vol.95, pp.4333-4337, 1998. ,
The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis, Bacteriol. Rev, vol.40, pp.681-697, 1976. ,
Differential activation of peroxisome proliferator-activated receptors by eicosanoids, J. Biol. Chem, vol.270, pp.23975-23983, 1995. ,
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation, Cell, vol.83, pp.813-819, 1995. ,
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma, Cell, vol.83, pp.803-812, 1995. ,
Interleukin-4-dependent production of PPARgamma ligands in macrophages by 12/15-lipoxygenase, Nature, vol.400, pp.378-382, 1999. ,
Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner, FEBS Lett, vol.471, pp.34-38, 2000. ,
Clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency, Arteriosclerosis, vol.4, pp.303-322, 1984. ,
The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat, Biochim. Biophys. Acta, vol.1167, pp.9-14, 1993. ,
Biotransformation of cerivastatin in mice, rats, and dogs in vivo, Drug. Metab. Dispos, vol.26, pp.640-652, 1998. ,
Effect of low density lipoproteins, high density lipoproteins, and cholesterol on apolipoprotein A-I mRNA in Hep G2 cells, FEBS Lett, vol.243, pp.213-217, 1989. ,
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction, JAMA, vol.279, pp.1643-1650, 1998. ,
Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay, Mol. Endocrinol, vol.11, pp.779-791, 1997. ,
HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture, Toxicol. Appl. Pharmacol, vol.145, pp.99-110, 1997. ,
Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation, Biochem. Biophys. Res. Commun, vol.206, pp.637-643, 1995. ,
The prenylation of proteins, Bioessays, vol.14, pp.25-31, 1992. ,
Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha, J. Biol. Chem, vol.275, pp.11484-11491, 2000. ,
Regulation of the mevalonate pathway, Nature, vol.343, pp.425-430, 1990. ,
Protein lipidation in cell signaling, Science, vol.268, pp.221-225, 1995. ,
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1), J. Biol. Chem, vol.274, pp.21926-21931, 1999. ,
Bacterial toxins that target Rho proteins, J. Clin. Invest, vol.99, pp.827-829, 1997. ,
Rho GTPases and the actin cytoskeleton, Science, vol.279, pp.509-514, 1998. ,
The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway, Cell, vol.81, pp.1137-1146, 1995. ,
Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs, Cell, vol.81, pp.1147-1157, 1995. ,
The small GTP-binding protein rho activates c-Jun N-terminal kinases/stress-activated protein kinases in human kidney 293T cells. Evidence for a Pak-independent signaling pathway, J. Biol. Chem, vol.271, pp.25731-25734, 1996. ,
The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin, Endocrinology, vol.137, pp.4499-4502, 1996. ,
Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth, J. Clin. Invest, vol.105, pp.1723-1730, 2000. ,
Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain, J. Biol. Chem, vol.274, pp.10505-10510, 1999. ,
Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of PPAR alpha transcriptional activity mediated by stat5b, J. Biol. Chem, vol.274, pp.2672-2681, 1999. ,
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism, Mol. Cell. Biol, vol.19, pp.5495-5503, 1999. ,